Australasian Journal of Dermatology最新文献

{"title":"Patient Perspectives on Dupilumab Therapy for Atopic Dermatitis: Experiences, Expectations and Treatment Impact.","authors":"Nadine Abu-Ghazaleh, Gayle Ross, Vanessa Morgan","doi":"10.1111/ajd.70193","DOIUrl":"https://doi.org/10.1111/ajd.70193","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterised by epidermal barrier dysfunction and type 2 immune dysregulation. Dupilumab was the first biologic approved for severe AD and has transformed management of moderate-to-severe disease. Although clinical trials and international real-world studies have demonstrated sustained efficacy and acceptable tolerability, Australian data describing patient-reported experience with dupilumab remain limited.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey study of adults receiving dupilumab for moderate-to-severe AD at the Royal Melbourne Hospital dermatology clinic. Over a two-month period, QR codes linked to an anonymous electronic questionnaire displayed in waiting areas and consultation rooms. Survey data were collected and managed using REDCap (Research Electronic Data Capture). The questionnaire examined treatment administration, perceived effectiveness, symptom change, treatment satisfaction, ocular and non-ocular adverse effects and concomitant therapy use.</p><p><strong>Results: </strong>During the recruitment period, 68 patients receiving dupilumab attended clinic and were eligible to participate; 48 completed the survey, corresponding to a response rate of 70.6%. Most respondents reported marked clinical benefit, with 66.7% reporting significant improvement in eczema control and 22.9% reporting complete resolution. Overall satisfaction was high, with 83.3% reporting being satisfied or very satisfied with treatment. Dupilumab was perceived as more effective than previous therapies by 83.3% of patients. Ocular symptoms were common amongst the cohort.</p><p><strong>Conclusions: </strong>In this tertiary australian cohort, patients treated with dupilumab reported high satisfaction and Substantial improvement in disease control and quality of life. These findings support the real-world effectiveness of dupilumab and highlight the importance of proactive recognition and management of ocular adverse effects.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermoscopic Features of Mpox: A Case Series.","authors":"Ilse Andrea Moreno-Arquieta, Héctor Teodoro Rios-Bazaldua, Roger Adrián González-Ramírez, Gabriel Salerni, Erika Stephania Alvarado-Arana, José Alberto García-Lozano, Juan Pablo Gonzalez-Morales, Jesus Alberto Cardenas-de la Garza","doi":"10.1111/ajd.70197","DOIUrl":"https://doi.org/10.1111/ajd.70197","url":null,"abstract":"<p><p>Monkeypox (mpox) is a viral infection characterized by polymorphic cutaneous lesions and systemic symptoms, including fever, lymphadenopathy, headache and myalgia. Given its broad differential diagnosis, accurate recognition requires a high level of clinical suspicion; in this context, dermoscopy represents a potentially useful tool to improve diagnostic accuracy. We conducted a retrospective case series of six patients with RT-PCR-confirmed mpox and dermatologic involvement between July 2022 and July 2025. A total of six patients were included; three (50%) were evaluated in the macular/vesicular phase and three (50%) in the crusted phase. In the macular/vesicular phase, eight lesions were analysed. In the crusted phase, five lesions were analysed. In our series, we observed pinkish-yellow structureless areas during the macular/vesicular phase. Recognition of these dermoscopic features may increase clinical suspicion and support the diagnosis.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Roflumilast in Lichen Planus: A Prospective Real-World Case Series of Ten Adults.","authors":"Francisco José Navarro-Triviño, David Moyano-Bueno, José María Llamas-Molina, Ricardo Ruiz-Villaverde, Francisco Javier de la Torre-Gomar","doi":"10.1111/ajd.70198","DOIUrl":"10.1111/ajd.70198","url":null,"abstract":"<p><p>Lichen planus (LP) is a chronic inflammatory dermatosis with limited systemic treatment options, and prospective data on oral phosphodiesterase-4 (PDE4) inhibition are lacking. We conducted a prospective real-world case series of ten adults with clinically and/or histologically confirmed LP treated with oral roflumilast, assessing disease severity using the Investigator's Global Assessment (IGA), pruritus and sleep disturbance using Numeric Rating Scales (NRS) and quality of life using the Dermatology Life Quality Index (DLQI). At baseline, 90% of patients presented moderate-to-severe disease (IGA 3-4). By week 12, 7 of 9 evaluable patients (78%) achieved IGA 0-1, increasing to 6 of 7 evaluable patients (86%) at week 24. Mean pruritus NRS improved from 7.7 to 1.6, sleep disturbance NRS from 7.3 to 2.0 and DLQI from 12.0 to 3.6. Overall, eight patients (80%) achieved at least 75% clinical improvement and six (60%) complete remission. The most frequent adverse events were insomnia (50%) and loose stools (30%), and two patients (20%) discontinued treatment because of adverse events. These preliminary prospective real-world findings suggest that oral roflumilast may represent a potential therapeutic option for LP and support further controlled studies to define the role of PDE4 inhibition and optimal dosing in this condition.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence Gaps in Prediction Tools for Follow Up After Localised Melanoma.","authors":"Deonna M Ackermann, Xu Huang, Ellie Medcalf, Katy J L Bell","doi":"10.1111/ajd.70196","DOIUrl":"https://doi.org/10.1111/ajd.70196","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Severe Face and Neck Rosacea-Like Pustular Eruption Associated With Upadacitinib in the Treatment of Severe Atopic Dermatitis.","authors":"Aimal Fatima, Genevieve Casey","doi":"10.1111/ajd.70195","DOIUrl":"https://doi.org/10.1111/ajd.70195","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sebopsoriasis Arising After Upper Eyelid Reconstruction With a Postauricular Full-Thickness Skin Graft.","authors":"Zahra Almosawy, Rebecca Nguyen","doi":"10.1111/ajd.70194","DOIUrl":"https://doi.org/10.1111/ajd.70194","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab as an Effective Adjuvant Therapy for Corticosteroid-Refractory Lichenoid-Bullous Dermatitis Secondary to Pembrolizumab","authors":"Brandon Tan,&nbsp;Gaurav N. Pathak,&nbsp;Alexis Lara Rivero","doi":"10.1111/ajd.70147","DOIUrl":"10.1111/ajd.70147","url":null,"abstract":"&lt;p&gt;Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape in oncology; however, cutaneous immune-related adverse events (cirAEs), affecting 30%–50% of patients [&lt;span&gt;1&lt;/span&gt;], often complicate management. Lichenoid eruptions occur in approximately 6% of cirAEs and may lead to interruption or discontinuation of immunotherapy, potentially impacting prognosis. Current guidelines do not specifically address lichenoid reactions, limiting treatment to systemic corticosteroids and discontinuation of immunotherapy [&lt;span&gt;2&lt;/span&gt;]. Dupilumab, an interleukin-4 receptor alpha (IL-4Rα) antagonist targeting IL-4/IL-13 signalling, has recently garnered attention as potential targeted therapy for ICI-induced lichenoid dermatitis (ICILD), based on RNA in situ hybridisation studies demonstrating IL-13 expression in affected skin [&lt;span&gt;3&lt;/span&gt;]. We present a unique case of severe lichenoid-bullous reaction successfully treated with dupilumab, without clinical evidence of progression.&lt;/p&gt;&lt;p&gt;A 61-year-old woman was admitted to hospital for urgent dermatological review following a 10-day history of widespread confluent erythematous rash with tense bullae (Figure 1A), oral mucositis (Figure 1B), and constitutional symptoms. She had received combination gemcitabine, carboplatin, and pembrolizumab nine months earlier for metastatic triple-negative PD-L1-positive breast cancer, followed by two doses of maintenance pembrolizumab monotherapy within the past month. Past medical history included type 1 diabetes mellitus and pulmonary embolism. The patient was commenced on silver-based wound dressings, topical betamethasone dipropionate 0.05% ointment, oral prednisolone 50 mg twice daily, and oral mycophenolate mofetil (MMF) 1000 mg twice daily. By week 2, progressive mucosal involvement and rapid denuding of palmoplantar skin (Figure 1C,D) were observed. Skin biopsy demonstrated moderate-to-severe interface dermatitis, subepidermal clefting, and numerous Civatte bodies without epidermal necrosis (Figure 2). Direct immunofluorescence and autoimmune blistering serology were negative. Given involvement of greater than 50% body surface area and oral mucosa, the diagnosis of grade 4 lichenoid-bullous drug reaction was made, warranting permanent discontinuation of pembrolizumab.&lt;/p&gt;&lt;p&gt;This case is among the first to support an emerging role for dupilumab in treating ICILD. By targeting IL-4/IL-13 signalling and Th2-driven inflammation [&lt;span&gt;3&lt;/span&gt;], dupilumab may reduce reliance on high-dose corticosteroids and associated metabolic adverse effects. Recent studies support clinical efficacy and safety of dupilumab in treating classic lichen planus [&lt;span&gt;4&lt;/span&gt;] and bullous pemphigoid [&lt;span&gt;5&lt;/span&gt;], highlighting its role in ICILD and immunobullous cirAEs, respectively [&lt;span&gt;3&lt;/span&gt;]. Future studies should evaluate dupilumab on a larger scale to establish its safety and efficacy in treating severe cirAEs.&lt;/p&gt;&lt;p&gt;The authors have nothing to report","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"320-322"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Sunscreen Awareness and Misconceptions in Skin of Colour With Acne-Related Post-Inflammatory Hyperpigmentation: A Cross-Sectional Study Highlighting the Need for Targeted Education","authors":"Xiaozhun Hang,&nbsp;Davin Sui Lim,&nbsp;Lisa Byrom","doi":"10.1111/ajd.70083","DOIUrl":"10.1111/ajd.70083","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Post-inflammatory hyperpigmentation (PIH) is a frequent sequela of acne in patients with skin of colour (SOC). While sunscreen is widely recommended for PIH prevention, little is known about real-world sunscreen practices in this group. This study aimed to evaluate sunscreen use, barriers and factors influencing adherence in SOC patients with acne-related PIH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional survey was conducted on 51 SOC patients (FST III–VI) who attended a dermatology clinic in Australia between February and June 2025. An investigator-developed questionnaire assessed sunscreen use frequency, reapplication, application amount, tinted sunscreen uptake, and perceived barriers. Associations were examined using chi-square/Fisher's exact tests and logistic regression analyses. Analyses were exploratory.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Daily sunscreen use was inconsistent, with 39.2% applying occasionally (&lt; 3 times/week) and only 33.3% applying daily. Reapplication was inadequate, with 57.5% (23/40) reapplying only when outdoors for prolonged periods. Most patients (79.5%, 31/39) applied less than one finger-length to the head and neck. Tinted sunscreen uptake was low, though shade match was a key determinant of adherence among users. Few patients recognised sunscreen's role in PIH prevention (19.6%), with professional advice emerging as an important factor associated with correct belief (no advice vs. advice, OR 0.04, <i>p</i> = 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Sunscreen use among SOC patients with acne-related PIH was suboptimal, with inadequate daily use, reapplication, and quantities applied. Clinician-led education was a key factor in influencing patient beliefs, highlighting the need for targeted counselling. Expanding shade-diverse, cosmetically elegant, tinted formulations may further improve adherence in SOC populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e299-e306"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatology Education in New South Wales and Australian Capital Territory Medical Schools: A Cross-Sectional Study","authors":"Sophie Walter,&nbsp;Artiene Tatian,&nbsp;Linda K. Martin","doi":"10.1111/ajd.70122","DOIUrl":"10.1111/ajd.70122","url":null,"abstract":"&lt;p&gt;Dermatological conditions are among the most common reasons that patients seek medical attention in primary care settings. In Australia, skin-related presentations comprise 15.3% of all general practice consultations [&lt;span&gt;1&lt;/span&gt;]. Furthermore, Australia has the highest incidence of melanoma and non-melanoma skin cancer globally [&lt;span&gt;2&lt;/span&gt;]. Despite presentation frequency, dermatology teaching is often under-represented in medical schools [&lt;span&gt;3&lt;/span&gt;]. Previous studies of graduating medical students in Australia and abroad have reported low confidence in diagnosing and managing common skin diseases [&lt;span&gt;4, 5&lt;/span&gt;]. A recent survey found that Australian general practitioners rated skin cancer a top learning priority [&lt;span&gt;6&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;There is no agreed standard across Australian universities that outlines the necessary dermatology competencies for medical graduates. Consequently, the integration of dermatology into medical curricula varies substantially between institutions [&lt;span&gt;3&lt;/span&gt;]. The study aim was to assess the quantity, structure and content of dermatology teaching across medical schools in New South Wales (NSW) and Australian Capital Territory (ACT) and identify gaps that may inform the development of a national curriculum.&lt;/p&gt;&lt;p&gt;A cross-sectional study was conducted to assess dermatology teaching across the eight medical schools in NSW and ACT. From May to October 2025, the medical schools were invited to provide information about dermatology education within their curriculum, including topics taught, mode of content delivery, professional background of educators, total duration of dermatology teaching, phase of the medical course in which teaching occurred and whether the content was formally assessed. Given the prevalence of skin cancer in Australia, dermato-oncology teaching was examined in detail. Data were obtained by inspection of written curricula and correspondence with key university personnel.&lt;/p&gt;&lt;p&gt;All eight institutions gave information about dermatology education, although information from one institution was limited (Data S1).&lt;/p&gt;&lt;p&gt;Dermatology topics taught at medical schools (Figure 1) ranged from 3 to 17. Only one institution specifically addressed dermatological conditions affecting Aboriginal and Torres Strait Islander peoples. The median duration of total dermatology teaching was 13 h (range 9–62 h), including 3–29 didactic hours (range), with the remainder being self-directed. A median of 45% (range 0%–100%) of content was delivered by dermatologists or dermatology registrars. All respondent institutions used lectures and tutorials as the primary mode of content delivery. Most dermatology teaching occurred during the later clinical years.&lt;/p&gt;&lt;p&gt;Table 1 summarises skin cancer education across institutions. The most common topics were clinical features (&lt;i&gt;N&lt;/i&gt; = 6) and management (&lt;i&gt;N&lt;/i&gt; = 6). Only one institution had a teaching session on dermoscopy. A median of 2.5 h (range 0.5–10.5 ","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"316-319"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70122","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab's Real-World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis","authors":"Paul Sun Woo Kim,&nbsp;Jacqueline Tu,&nbsp;Kelvin Truong,&nbsp;Gloria Fong,&nbsp;William Luu,&nbsp;Peter Barclay,&nbsp;Melanie Wong,&nbsp;Li-Chuen Wong","doi":"10.1111/ajd.70118","DOIUrl":"10.1111/ajd.70118","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Dupilumab is an anti-interleukin (IL)-4 receptor (IL-4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real-world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups. This study evaluated dupilumab's efficacy and safety at an Australian tertiary centre.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All paediatric AD patients (&lt; 18 years old) treated with dupilumab at a tertiary centre with available follow-up data were retrospectively analysed. Effectiveness was measured using the Eczema Area and Severity Index (EASI), Children's Dermatology Life Quality Index (cDLQI), and Physician Global Assessment (PGA). Adverse events (AEs) were recorded. Differences in efficacy and safety between age groups (0–5, 6–11, 12–17 years old) were analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>103 patients (9.2 ± 3.8 years old, 51.5% male) were analysed with a follow-up of 495.3 ± 337.3 days. 95.1%, 90.1% and 66.7% of patients achieved a 50%, 75%, 90% drop in EASI (EASI-50, EASI-75, EASI-90). 93.4% and 94.7% of patients achieved a 6-point drop in cDLQI and a 2-point drop in PGA. 43.2%, 48.7% and 71.1% of patients achieved EASI ≤ 1, cDLQI ≤ 1 and PGA ≤ 1 respectively. Two patients discontinued dupilumab due to AEs (psoriasis flare and lichenoid drug-reaction). 49 (47.6%) patients experienced AEs, with the most frequent category being ocular-related (<i>n</i> = 43). There were no statistically significant differences between age groups in the rate of achieving efficacy thresholds or in the rate of AEs for each AE category. Median time-to-effect for EASI-50/75/90 were 130, 140 and 291 days on Kaplan–Meier analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Paediatric dupilumab patients experienced significant improvements with an acceptable safety profile, independent of age.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"301-308"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70118","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}